BRAF V600EPhase 3 RCT (updated)NEJM 2025來源:人工整理
EC+mFOLFOX6 vs SOC (1L)
關鍵結果mPFS 12.8 vs 7.1 mo; mOS 30.3 vs 15.1 mo, HR 0.49
mOS 30.3 個月——BRAF V600E mCRC 首次追上 BRAF wt 的存活。死亡風險減半
詳細證據整理
Encorafenib, Cetuximab and mFOLFOX6 in BRAF-Mutant Colorectal Cancer
Abstract
BACKGROUND: The open-label, phase 3 BREAKWATER study evaluated first-line encorafenib plus cetuximab with or without chemotherapy (oxaliplatin, leucovorin, and 5-FU) (EC+/-mFOLFOX6) vs. standard of care (SOC; chemotherapy with or without bevacizumab) in BRAF V600E-mutant metastatic colorectal cancer (mCRC), an aggressive subtype with poor prognosis. BREAKWATER previously met one of its dual primary endpoints, objective response rate by blinded independent central review (60.9% [EC+mFOLFOX6] vs. 40.0% [SOC], odds ratio=2.443, one-sided P=0.0008), leading to accelerated FDA approval of EC+mFOLFOX6 for patients with BRAF V600E-mutant mCRC, including in the first-line setting. We report here the primary analysis of progression-free survival and an updated interim analysis of overall survival.
METHODS: In BREAKWATER, patients with previously untreated BRAF V600E-mutant mCRC were randomized to receive EC, EC+mFOLFOX6 or SOC. The dual primary endpoints were objective response rate and progression-free survival by blinded independent central review. The key secondary endpoint was overall survival.
RESULTS: BREAKWATER met its other dual primary endpoint, demonstrating significant progression-free survival improvement with EC+mFOLFOX6 vs. SOC: hazard ratio (HR) 0.53 (95% confidence interval [CI] 0.407, 0.677; two-sided P<0.0001); median progression-free survival 12.8 vs. 7.1 months. Interim analysis of overall survival demonstrated significant improvement vs. SOC: HR 0.49 (95% CI 0.375, 0.632; two-sided P<0.0001); median overall survival 30.3 vs. 15.1 months. Serious treatment-emergent adverse event rates were 46.1% vs. 38.9%; safety profiles were consistent with those known for each agent.
CONCLUSION: BREAKWATER demonstrated statistically significant improvements in progression-free and overall survival with first-line EC+mFOLFOX6 vs. SOC in patients with BRAF V600E-mutant mCRC.
Introduction
Approximately 8-12% of metastatic colorectal cancers (mCRCs) harbor BRAF V600E mutations. BRAF V600E-mutant mCRC has emerged as a distinct mCRC subtype characterized by poor prognosis versus BRAF wild-type disease and lower responses to chemotherapy. Encorafenib is a highly selective, ATP-competitive, small molecule BRAF inhibitor with anti-proliferative and apoptotic activity in tumor cells expressing V600E mutations and has prolonged pharmacodynamic activity compared with other approved BRAF inhibitors. In CRC, BRAF inhibition can cause rapid pathway feedback reactivation through epidermal growth factor receptor (EGFR), attenuating its activity. The value of simultaneously targeting BRAF with EGFR inhibition to overcome reactivation has been previously shown.
Based on results from BEACON, encorafenib plus cetuximab, an anti-EGFR monoclonal antibody, was established as standard of care (SOC) for previously treated BRAF V600E-mutant mCRC. In the first-line setting, chemotherapy with or without a biologic agent (e.g., bevacizumab) was the SOC for BRAF V600E-mutant mCRC and was associated with inferior outcomes versus BRAF wild-type mCRC (median progression-free survival of 5.8 vs. 9.2 months; median overall survival of 11.1 vs. 23.7 months). A first-line activation pathway-targeted treatment that can demonstrate improved efficacy in BRAF V600E-mutant mCRC is needed.
BREAKWATER is a phase 3 study evaluating encorafenib plus cetuximab (EC) with or without chemotherapy (mFOLFOX6) versus SOC, investigator's choice of chemotherapy (mFOLFOX6; FOLFOXIRI; or CAPOX) with or without bevacizumab, for the first-line treatment of patients with BRAF V600E-mutant mCRC. BREAKWATER previously met one of the dual primary endpoints, objective response rate by blinded independent central review in the objective response rate analysis set (n=220), demonstrating statistically significant improvement in confirmed objective response rate with EC+mFOLFOX6 vs. SOC (60.9% vs. 40.0%, odds ratio=2.443, one-sided P=0.0008). Based on these results, EC+mFOLFOX6 was granted accelerated approval by the US Food and Drug Administration (FDA), as part of the FDA's Project FrontRunner. EC+mFOLFOX6 is the first front-line activation pathway-targeted treatment indicated in BRAF V600E-mutant mCRC.
Reported here is the primary analysis of progression-free survival by blinded independent central review, the second dual primary endpoint, along with the updated interim analysis of overall survival, safety, and descriptive analyses of other secondary endpoints.
Methods
Trial Design, Patients, and Treatment
BREAKWATER is an ongoing, open-label, global, randomized, phase 3 trial enrolling in 28 countries. Patients who were at least 16 years of age, with histologically or cytologically confirmed colorectal adenocarcinoma with Stage IV metastatic disease, measurable disease (RECIST version 1.1), and presence of a BRAF V600E mutation assessed by local or central laboratory testing were eligible. Exclusion criteria included prior systemic treatment for metastatic disease, prior BRAF or EGFR inhibitor, symptomatic brain metastases, MSI-H/dMMR tumors (unless ineligible to receive immune checkpoint inhibitors), or a RAS mutation.
Patients were randomized 1:1:1 to receive EC (encorafenib 300 mg orally once daily; cetuximab 500 mg/m² intravenously once every 2 weeks), EC+mFOLFOX6 (encorafenib 300 mg orally once daily; cetuximab 500 mg/m² intravenously once every 2 weeks; oxaliplatin 85 mg/m², leucovorin 400 mg/m², and 5-FU 400 mg/m² intravenous bolus, then 5-FU 2400 mg/m² continuous intravenous infusion over 46-48 hours, all once every 2 weeks [mFOLFOX6; 28-day cycle]), or investigator's choice SOC (mFOLFOX6, FOLFOXIRI, or CAPOX, each with or without bevacizumab). Following a protocol amendment, EC arm enrollment was stopped and patients were randomized 1:1 to receive EC+mFOLFOX6 or SOC.
Randomization stratification factors were ECOG performance status (0 vs. 1) and region (US/Canada vs. Europe vs. Rest of World).
Endpoints
The dual primary endpoints were objective response rate and progression-free survival by blinded independent central review. The key secondary endpoint was overall survival. Other secondary endpoints included time to response, duration of response, progression after next line of therapy (PFS2), patient-reported outcomes, pharmacokinetics, safety, and biomarker endpoints.
Progression-free survival after the next line of therapy (PFS2) is defined as the time from randomization to discontinuation of next-line treatment, second objective disease progression, or death from any cause, whichever occurs first.
Statistical Analysis
The primary analysis of progression-free survival was preplanned to occur after at least 230 events for the EC+mFOLFOX6 and SOC arms and at least 12 months after the completion of enrollment. The sample size (235 patients per arm) was determined based on the assumption of an HR of 0.67 with median PFS of 7 and 10.4 months in the SOC and EC+mFOLFOX6 arms, providing at least 85% power using a one-sided stratified log-rank test at a significance level of 0.023.
Results
Patients
Patients were enrolled between November 16, 2021, and December 22, 2023 in the phase 3 portion; 158, 236, and 243 patients were randomized to the EC, EC+mFOLFOX6, and SOC arms, respectively. In the SOC arm, 197 of 243 (81.1%) patients received bevacizumab with chemotherapy.
Efficacy
The data cutoff for the analyses was January 6, 2025.
Progression-Free Survival (Dual Primary Endpoint):
| Endpoint | EC+mFOLFOX6 (n=236) | SOC (n=243) |
|---|---|---|
| Median PFS follow-up | 16.8 months | 9.8 months |
| Median PFS | 12.8 months (95% CI 11.2-15.9) | 7.1 months (95% CI 6.8-8.5) |
| PFS HR | 0.53 (95% CI 0.407-0.677; two-sided P<0.0001) | |
Predefined subgroup analyses of PFS were consistent with the overall population. In the EC arm, median PFS was 6.8 months (95% CI 5.7-8.3).
Overall Survival (Key Secondary Endpoint - Updated Interim Analysis):
242 overall survival events (81.5% of 297 events expected for the final analysis) had occurred at the time of data cutoff; 94 (39.8%) in the EC+mFOLFOX6 arm and 148 (60.9%) in the SOC arm.
| Endpoint | EC+mFOLFOX6 (n=236) | SOC (n=243) |
|---|---|---|
| Median OS follow-up | 21.8 months | 22.2 months |
| OS events | 94 (39.8%) | 148 (60.9%) |
| Median OS | 30.3 months (95% CI 21.7-NE) | 15.1 months (95% CI 13.7-17.7) |
| OS HR | 0.49 (95% CI 0.375-0.632; two-sided P<0.0001) | |
| 12-month OS rate | 80.1% | 66.0% |
| 24-month OS rate | 52.0% | 29.0% |
In the EC arm, median OS was 19.5 months (95% CI 17.6-22.5), with a median follow-up of 26.3 months.
Objective Response Rate (Updated, All Randomized Patients):
| Endpoint | EC+mFOLFOX6 | SOC | EC alone |
|---|---|---|---|
| Confirmed ORR | 65.7% (95% CI 59.4-71.4) | 37.4% (95% CI 31.6-43.7) | 45.6% (95% CI 38.0-53.3) |
| Median TTR | 7.0 weeks | 7.3 weeks | 6.6 weeks |
| Median DOR | 13.9 months (95% CI 10.9-18.5) | 10.8 months (95% CI 7.6-13.4) | 7.0 months (95% CI 4.2-11.6) |
Subsequent Systemic Anticancer Treatments and PFS2
At data cutoff, among patients who discontinued treatment, 63.9% (108/169) and 61.2% (139/227) received subsequent systemic anticancer treatment in the EC+mFOLFOX6 and SOC arms, respectively; this was 73.3% in the EC arm. The majority of patients in the EC and EC+mFOLFOX6 arms received subsequent chemotherapies. Of the 139 patients in the SOC arm who received any subsequent systemic anticancer treatment, 100 (71.9%) received BRAF inhibitor-based subsequent therapies.
The median time to PFS2 was 20.7 months (95% CI 19.0-23.9) and 12.7 months (95% CI 11.2-13.7) in the EC+mFOLFOX6 and SOC arms, respectively, and 14.3 months (95% CI 12.7-16.6) in the EC arm.
Safety
The median duration of treatment was 27.0 weeks (EC), 49.8 weeks (EC+mFOLFOX6), and 25.9 weeks (SOC). At data cutoff, 12 (7.6%), 67 (28.4%), and 16 (6.6%) patients were still on study treatment, respectively.
| Safety Endpoint | EC (n=153) | EC+mFOLFOX6 (n=232) | SOC (n=227) |
|---|---|---|---|
| Any TEAE | 97.4% | 100% | 99.1% |
| Grade 3/4 AEs | 42.5% | 81.5% | 66.8% |
| Grade 5 AEs | 2.6% | 4.3% | 4.4% |
| Serious TEAEs | 30.1% | 46.1% | 38.9% |
| AEs leading to discontinuation | 13.1% | 26.7% | 17.5% |
| AEs leading to dose reduction | 10.5% | 65.5% | 54.1% |
The most frequent (≥30%) TEAEs in the EC+mFOLFOX6 arm were nausea (53.9%), anemia (46.1%), diarrhea (41.8%), decreased appetite (37.5%), vomiting (36.2%), neutrophil count decreased (34.1%), arthralgia (31.5%), and rash (30.2%). In the SOC arm, the most frequent were diarrhea (50.2%) and nausea (49.8%).
Permanent discontinuation of chemotherapy with or without bevacizumab due to adverse events was reported in 20.7% and 17.5% of patients in the EC+mFOLFOX6 and SOC arms; dose reduction of any of these interventions were reported in 59.9% and 54.1%, respectively.
Discussion
BREAKWATER has met both dual primary endpoints and the key secondary endpoint, showing statistically significant improvements with EC+mFOLFOX6 over the SOC arm in objective response rate, progression-free and overall survival in previously untreated BRAF V600E-mutant mCRC. The risk of disease progression or death in the EC+mFOLFOX6 arm was nearly halved (47% lower) vs. the SOC arm. Treatment with EC+mFOLFOX6 resulted in risk of death that was half (51% lower) of that in the SOC arm.
The early separation of the progression-free survival Kaplan-Meier curves indicates an early clinical benefit in the EC+mFOLFOX6 arm vs. the SOC arm. Survival advantage was further demonstrated by a median overall survival more than doubled in the EC+mFOLFOX6 arm vs. the SOC arm. Notably, median overall survival in the EC+mFOLFOX6 arm was 30.3 months, which is similar to the median overall survival reported in BRAF wild-type mCRC, despite the historically poor prognosis in BRAF-mutant vs wild-type mCRC. Both the progression-free and overall survival benefits of EC+mFOLFOX6 were observed across all predefined clinical subgroups, including in patients with liver metastases or at least 3 organs involved.
Median PFS2 was prolonged with EC+mFOLFOX6, and together with overall survival data, support the importance of a first-line treatment containing encorafenib to derive long-term clinical benefit. The subsequent anticancer treatments followed current real-world practices, with most of the SOC arm receiving subsequent BRAF inhibitor-based targeted treatments.
EC arm enrollment was closed based on the low likelihood of EC demonstrating superiority versus SOC following the results of the phase 2 ANCHOR study. PFS and OS data from the EC arm underscore the need for an intensive first-line regimen, such as EC+mFOLFOX6, to control aggressive tumor growth. Nevertheless, EC did show a numerically higher objective response rate, longer median OS, and early separation of OS Kaplan-Meier curves. However, median OS was shorter in the EC arm compared with EC+mFOLFOX6 arm. First-line EC may be considered for patients who are unable to tolerate chemotherapy.
EC plus FOLFIRI is currently being investigated in the ongoing cohort 3 portion of BREAKWATER. Additionally, SEAMARK is evaluating first-line EC with pembrolizumab vs. pembrolizumab alone in patients with BRAF V600E-mutant and MSI-H/dMMR mCRC.
BREAKWATER demonstrated an improved survival benefit with EC+mFOLFOX6 as a first-line treatment for patients with BRAF V600E-mutant mCRC.
本頁僅供醫療專業人員教育與臨床參考,不構成醫療建議;臨床決策請以原始文獻與現行指引為準。
讀者討論
讀者留言是個人意見,不是本站的文獻整理,也沒有經過醫學審核。
載入留言中…